Get the Stockscreener App
0.00
100.00%
-1.78
After Hours:
1.76
1.76
+
Trevena Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -60.53% over the past month.
See More
Previous Close:
$1.78
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
$3.13M
Net Income/Loss:
$-40.29M
P/E Ratio:
0.00
EPS:
-3.2
Net Cash Flow:
$-33.08M
1W Performance:
+14.81%
1M Performance:
-60.53%
6M Performance:
+427.32%
1Y Performance:
+221.67%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$1.78
52-Week Range:
$0.00
$1.78
Trevena Inc Stock (TRVN) Company Profile
Compare TRVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
0.00 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-21 | Initiated | Oppenheimer | Perform |
| Sep-14-20 | Initiated | Guggenheim | Buy |
| Aug-28-20 | Initiated | Cantor Fitzgerald | Overweight |
| May-31-19 | Resumed | H.C. Wainwright | Buy |
| Nov-05-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-12-18 | Downgrade | Needham | Buy → Hold |
| Oct-10-18 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-17 | Reiterated | Needham | Buy |
| Oct-16-17 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-12-17 | Reiterated | H.C. Wainwright | Buy |
| May-08-17 | Reiterated | Needham | Buy |
| Feb-23-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-17 | Reiterated | FBR & Co. | Outperform |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-09-17 | Initiated | H.C. Wainwright | Buy |
| Jan-05-17 | Initiated | Oppenheimer | Outperform |
| May-17-16 | Reiterated | FBR Capital | Outperform |
| May-17-16 | Reiterated | Needham | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
| Sep-01-15 | Reiterated | Wedbush | Outperform |
| Aug-03-15 | Initiated | Brean Capital | Buy |
View All
Trevena Inc Stock (TRVN) Latest News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks
Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - Defense World
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena discontinues OLINVYK injection sales By Investing.com - Investing.com Canada
Trevena discontinues OLINVYK injection sales - Investing.com
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com - Defense World
Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection - Reuters.com
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena Announces Reverse Stock Split to Regain Nasdaq Compliance - MSN
With a 1.8% CAGR, the Opioid Market is Expected to Reach USD 28.45 billion by 2034 | PMR - GlobeNewswire
Trevena's SWOT analysis: CNS drug developer's stock faces pivotal moment - Investing.com
Trevena's SWOT analysis: stock outlook amid pipeline focus and financial moves - Investing.com Canada
Trevena's SWOT analysis: stock outlook amid pipeline focus and financial moves By Investing.com - Investing.com South Africa
Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Compass Therapeutics Appoints Barry Shin as Chief Financial Officer - citybiz
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer - The Manila Times
Compass Therapeutics Taps Industry Veteran Barry Shin as CFO Ahead of Pivotal Clinical Data - StockTitan
Compass Therapeutics Names Barry Shin Chief Financial Officer - MarketWatch
Trevena appoints new financial chief - Investing.com
Trevena appoints new financial chief By Investing.com - Investing.com Nigeria
Trevena Appoints Katrine Sutton as New CFO - TipRanks
Trevena, Inc. Appoints Katrine Sutton as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com
Trevena, Inc. Navigates Financial Challenges and Strategic Changes - MSN
Post-operative Pain Therapeutics Market Future Prospects, - openPR
ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc - GuruFocus.com
Trevena downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Trevena Inc. Reports Q3 2024 Financial Results - TipRanks
What to look for when Lowe’s (LOW) reports Q3 2024 earnings results - AlphaStreet
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates - MSN
Postoperative Pain Therapeutics Market Trends, Business Overview, Industry Growth and Forecast to 2031 - openPR
Trevena Inc. (TRVN) Quarterly 10-Q Report - Quartz
Chester County biopharm firm's latest layoffs impact its C-suite - The Business Journals
Trevena: Q3 Earnings Snapshot - San Francisco Chronicle
Trevena Faces Leadership Changes Amidst Financial Challenges - TipRanks
Trevena, Inc. Announces Board Changes - Marketscreener.com
Trevena Reports Third Quarter 2024 Results and Provides Business Update - StockTitan
CVS Health books $1.2 bn in restructuring charges with new CEO comments in focus - MSN
Why Viking Therapeutics Stock Plummeted After Soaring Today - MSN
23andMe appoints new board members as it works to stem the company's slide - MSN
Sequoia buys South Carolina RIA Family Asset Management - MSN
Opioids Market Size to be worth $15.03 Billion By 2031: The Insight Partners - finanznachrichten.de
23andMe appoints three new board members following abrupt resignations - MSN
Post Operative Pain Therapeutics Market to Witness Huge Growth - openPR
Trevena Inc Stock (TRVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Cap:
|
Volume (24h):